Literature DB >> 22433865

Toll-like receptor activation of human cells by synthetic triacylated lipid A-like molecules.

Irène Dunn-Siegrist1, Pierre Tissières, Geneviève Drifte, Jacques Bauer, Stéphane Moutel, Jérôme Pugin.   

Abstract

Recognition of microbial molecules by mammalian host receptors is essential to mount an immune response. Hexaacylated LPS is the prototypic example of a bacterial molecule recognized by the receptor complex TLR4/MD-2 with its lipid A moiety, whereas bacterial lipopeptides are recognized by TLR2. Here we show that a series of synthetic triacylated lipid A-like molecules are weak Toll-like receptor (TLR) agonists (mainly TLR2 agonists) but very potent TLR4/MD-2 antagonists (submicromolar range). Not only do they block human cell responses to LPS but also to whole gram-negative bacteria, and they inhibit the phagocytosis of gram-negative bacteria. These compounds may represent promising immunomodulatory agents.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22433865      PMCID: PMC3351317          DOI: 10.1074/jbc.M112.348383

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  CD14 directly binds to triacylated lipopeptides and facilitates recognition of the lipopeptides by the receptor complex of Toll-like receptors 2 and 1 without binding to the complex.

Authors:  Takashi Nakata; Motoaki Yasuda; Mari Fujita; Hideo Kataoka; Kazuto Kiura; Hidehiko Sano; Kenichiro Shibata
Journal:  Cell Microbiol       Date:  2006-07-11       Impact factor: 3.715

2.  Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide.

Authors:  Mi Sun Jin; Sung Eun Kim; Jin Young Heo; Mi Eun Lee; Ho Min Kim; Sang-Gi Paik; Hayyoung Lee; Jie-Oh Lee
Journal:  Cell       Date:  2007-09-21       Impact factor: 41.582

3.  Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran.

Authors:  Ho Min Kim; Beom Seok Park; Jung-In Kim; Sung Eun Kim; Judong Lee; Se Cheol Oh; Purevjav Enkhbayar; Norio Matsushima; Hayyoung Lee; Ook Joon Yoo; Jie-Oh Lee
Journal:  Cell       Date:  2007-09-07       Impact factor: 41.582

4.  Phagocytosis and intracellular killing of MD-2 opsonized gram-negative bacteria depend on TLR4 signaling.

Authors:  Vishal Jain; Annett Halle; Kristen A Halmen; Egil Lien; Marie Charrel-Dennis; Sanjay Ram; Douglas T Golenbock; Alberto Visintin
Journal:  Blood       Date:  2008-01-18       Impact factor: 22.113

5.  Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1.

Authors:  Irene Dunn-Siegrist; Olivier Leger; Bruno Daubeuf; Yves Poitevin; Fabien Dépis; Suzanne Herren; Marie Kosco-Vilbois; Yann Dean; Jérôme Pugin; Greg Elson
Journal:  J Biol Chem       Date:  2007-10-05       Impact factor: 5.157

6.  A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route.

Authors:  Laurent Mascarell; Laurence Van Overtvelt; Vincent Lombardi; Alain Razafindratsita; Hélène Moussu; Stéphane Horiot; Henri Chabre; David Limal; Stéphane Moutel; Jacques Bauer; Carlo Chiavaroli; Philippe Moingeon
Journal:  Vaccine       Date:  2007-11-09       Impact factor: 3.641

7.  The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14.

Authors:  Sylvette Bas; Laurence Neff; Madeleine Vuillet; Ursula Spenato; Tsukasa Seya; Misako Matsumoto; Cem Gabay
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

8.  Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia.

Authors:  Annalisa Lembo; Mark Pelletier; Ravi Iyer; Michele Timko; Jan C Dudda; T Eoin West; Christopher B Wilson; Adeline M Hajjar; Shawn J Skerrett
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

9.  MD-2 as the target of curcumin in the inhibition of response to LPS.

Authors:  Helena Gradisar; Mateja Mancek Keber; Primoz Pristovsek; Roman Jerala
Journal:  J Leukoc Biol       Date:  2007-07-03       Impact factor: 4.962

10.  Soluble MD-2 is an acute-phase protein and an opsonin for Gram-negative bacteria.

Authors:  Pierre Tissières; Irène Dunn-Siegrist; Michela Schäppi; Greg Elson; Rachel Comte; Vandack Nobre; Jérôme Pugin
Journal:  Blood       Date:  2007-12-04       Impact factor: 22.113

View more
  5 in total

1.  Species-Dependent Blood-Brain Barrier Disruption of Lipopolysaccharide: Amelioration by Colistin In Vitro and In Vivo.

Authors:  Liang Jin; Roger L Nation; Jian Li; Joseph A Nicolazzo
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

2.  Synthesis of anti-inflammatory α-and β-linked acetamidopyranosides as inhibitors of toll-like receptor 4 (TLR4).

Authors:  Peter Wipf; Benjamin R Eyer; Yukihiro Yamaguchi; Feng Zhang; Matthew D Neal; Chhinder P Sodhi; Misty Good; Maria Branca; Thomas Prindle; Peng Lu; Jeffrey L Brodsky; David J Hackam
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

3.  Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update.

Authors:  Francesco Peri; Valentina Calabrese
Journal:  J Med Chem       Date:  2013-11-20       Impact factor: 7.446

Review 4.  Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships.

Authors:  Mehfuz Zaman; Istvan Toth
Journal:  Front Immunol       Date:  2013-10-09       Impact factor: 7.561

5.  MPL Adjuvant Contains Competitive Antagonists of Human TLR4.

Authors:  Yi-Qi Wang; Hélène Bazin-Lee; Jay T Evans; Carolyn R Casella; Thomas C Mitchell
Journal:  Front Immunol       Date:  2020-10-16       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.